Paper34745993
Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.
Yu Z and 9 others. Front Oncol, 2021. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study. Papers, record 34745993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34745993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27697982 | Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2016 | https://conductscience.org/library/papers/27697982 | PubMed |
| 2 | 27221832 | Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches. | Asian Pac J Cancer Prev | 2016 | https://conductscience.org/library/papers/27221832 | PubMed |
| 3 | 25862137 | Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol. | Clin Ther | 2015 | https://conductscience.org/library/papers/25862137 | PubMed |
| 4 | 24417770 | Hypersensitivity to oxaliplatin: clinical features and risk factors. | BMC Pharmacol Toxicol | 2014 | https://conductscience.org/library/papers/24417770 | PubMed |
| 5 | 15461551 | A review of oxaliplatin and its clinical use in colorectal cancer. | Expert Opin Pharmacother | 2004 | https://conductscience.org/library/papers/15461551 | PubMed |
| 6 | 27166187 | Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials. | Oncotarget | 2016 | https://conductscience.org/library/papers/27166187 | PubMed |
| 7 | 34403109 | Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis. | Curr Med Sci | 2021 | https://conductscience.org/library/papers/34403109 | PubMed |
| 8 | 20346128 | Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. | J Hematol Oncol | 2010 | https://conductscience.org/library/papers/20346128 | PubMed |
| 9 | 12888815 | Hypersensitivity reactions related to oxaliplatin (OHP). | Br J Cancer | 2003 | https://conductscience.org/library/papers/12888815 | PubMed |
| 10 | 28391355 | Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer. | Cancer Chemother Pharmacol | 2017 | https://conductscience.org/library/papers/28391355 | PubMed |
| 11 | 27989485 | Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review. | Clin Colorectal Cancer | 2016 | https://conductscience.org/library/papers/27989485 | PubMed |
| 12 | 28687576 | NCCN Guidelines Insights: Antiemesis, Version 2.2017. | J Natl Compr Canc Netw | 2017 | https://conductscience.org/library/papers/28687576 | PubMed |
| 13 | 24769036 | Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity. | Gynecol Oncol | 2014 | https://conductscience.org/library/papers/24769036 | PubMed |
| 14 | 28542731 | Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. | Br J Surg | 2017 | https://conductscience.org/library/papers/28542731 | PubMed |
| 15 | 19033714 | Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. | Oncology | 2009 | https://conductscience.org/library/papers/19033714 | PubMed |
| 16 | 22154408 | Literature review and practical aspects on the management of oxaliplatin-associated toxicity. | Clin Colorectal Cancer | 2012 | https://conductscience.org/library/papers/22154408 | PubMed |
| 17 | 12422304 | Oxaliplatin-related side effects: characteristics and management. | Semin Oncol | 2002 | https://conductscience.org/library/papers/12422304 | PubMed |
| 18 | 27461601 | Oxaliplatin-induced acute thrombocytopenia. | J Cancer Res Ther | 2016 | https://conductscience.org/library/papers/27461601 | PubMed |
| 19 | 22534771 | Oxaliplatin-related thrombocytopenia. | Ann Oncol | 2012 | https://conductscience.org/library/papers/22534771 | PubMed |
| 20 | 20497869 | Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. | J Formos Med Assoc | 2010 | https://conductscience.org/library/papers/20497869 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42741551 | Oxaliplatin-induced autoimmune-like hepatitis: A case report highlighting the role of clinical pharmacists. | Biomed Rep | 2026 | https://conductscience.org/library/papers/42741551 | PubMed |
| 42396160 | Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42396160 | PubMed |
| 42072487 | Synergistic Interactions Between Medicinal Plant Bioactive and Standard Chemotherapy in Gastric Cancer: Preclinical Evidence and Translational Pitfalls. | Biomedicines | 2026 | https://conductscience.org/library/papers/42072487 | PubMed |
| 41868970 | Lineage-Specific Disruption of Hematopoiesis by Oxaliplatin: Mechanisms of Erythropoietin Resistance and Immune Suppression. | J Hematol Oncol Res | 2026 | https://conductscience.org/library/papers/41868970 | PubMed |
| 41127694 | Oxaliplatin-Induced Hypersensitivity Reactions Resulting in Respiratory and Cardiac Arrest: A Rare Case. | Clin Case Rep | 2025 | https://conductscience.org/library/papers/41127694 | PubMed |
| 40792484 | Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death. | Angew Chem Int Ed Engl | 2025 | https://conductscience.org/library/papers/40792484 | PubMed |
| 40766760 | Prophylactic administration of lecithinized superoxide dismutase for a murine model of oxaliplatin-induced myelosuppression. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40766760 | PubMed |
| 39286172 | Huaier relieves oxaliplatin-induced hepatotoxicity through activation of the PI3K/AKT/Nrf2 signaling pathway in C57BL/6 mice. | Heliyon | 2024 | https://conductscience.org/library/papers/39286172 | PubMed |
| 38948470 | Risk of immune system and skin and subcutaneous tissue related adverse events associated with oxaliplatin combined with immune checkpoint inhibitors: a pharmacovigilance study. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38948470 | PubMed |
| 38400666 | Prediction for oxaliplatin-induced liver injury using patient-derived liver organoids. | Cancer Med | 2024 | https://conductscience.org/library/papers/38400666 | PubMed |
| 38161498 | Predictive Model of Oxaliplatin-induced Liver Injury Based on Artificial Neural Network and Logistic Regression. | J Clin Transl Hepatol | 2023 | https://conductscience.org/library/papers/38161498 | PubMed |
| 36899361 | Effects of Leea indica leaf extracts and its phytoconstituents on natural killer cell-mediated cytotoxicity in human ovarian cancer. | BMC Complement Med Ther | 2023 | https://conductscience.org/library/papers/36899361 | PubMed |
| 36833125 | The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients. | Healthcare (Basel) | 2023 | https://conductscience.org/library/papers/36833125 | PubMed |
| 36552030 | Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review. | Biomedicines | 2022 | https://conductscience.org/library/papers/36552030 | PubMed |
| 36330002 | Case report: Acute toxic myocardial damage caused by 5-fluorouracil-from enigma to success. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/36330002 | PubMed |
| 36245029 | Attention and Intervention of Oncologists on Oxaliplatin-induced Adverse Reactions in Mainland China: A Cross-sectional Internet-based Survey. | Curr Med Sci | 2022 | https://conductscience.org/library/papers/36245029 | PubMed |
| 35919789 | Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study. | Pharm Pract (Granada) | 2022 | https://conductscience.org/library/papers/35919789 | PubMed |
| 35833185 | Case Report: Oxaliplatin-Induced Third-Degree Atrioventricular Block: First Discovery of an Important Side-Effect. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/35833185 | PubMed |
| 35739960 | Antioxidant and Neuroprotective Effect of a Grape Pomace Extract on Oxaliplatin-Induced Peripheral Neuropathy in Rats: Biochemical, Behavioral and Histopathological Evaluation. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/35739960 | PubMed |
| 35559366 | Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer. | Am J Transl Res | 2022 | https://conductscience.org/library/papers/35559366 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34745993
GET https://conductscience.org/api/papers/v1/34745993/references?page=2